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TO THE EDITOR
Dermatomyositis (DM) is a rare systemic
autoimmune disease characterized by
inflammation of the skin and muscle.
Skin rash in DM may precede the onset
of muscle disease by months to years,
and in some cases overt muscle disease
may remain mild or never occur.
DM skin disease manifests in varied ways
including facial edema, pink to violac-
eous patches on the eyelids (heliotrope
sign), violaceous scaly plaques with
atrophy on the shoulders and hips,
violaceous atrophic scaling papules on
the interphalangeal joints (Gottron’s
papules), and prominent nailfold telan-
giectasias. However, these findings are
variably present, and DM skin disease
can share clinical features with cuta-
neous lupus, overlap connective tissue
disease syndromes, UV light–induced
reactions, and psoriasis (Sontheimer,
2002), often creating diagnostic
difficulty at early presentation.
Psoriasis is an inflammatory skin
disease most commonly characterized
by well-demarcated plaques with
micaceous scales. Histopathologically,
psoriasis displays epidermal acanthosis,
confluent parakeratosis, subcorneal
neutrophils, and thinning of the supra-
papillary plate. In contrast, DM is
characterized by an interface dermatitis
with a superficial perivascular infiltrate,
and dermal mucin deposition. However,
DM patients often present with erythe-
matous scaly plaques in the scalp or
on extremities, which can be clinically
confused with psoriasis. In addition,
many skin biopsies of DM can actually
show minimal to no interface dermatitis,
and have evidence of neutrophilic inflam-
mation (Ito et al., 1995; Caproni et al.,
2004), perivascular dermatitis, and even
epidermal hyperplasia not dissimilar to
that seen in psoriasis.
Molecular profiling has widely been
used to aid the diagnosis of cancer
patients since the publication of land-
mark work by Golub et al. (1999). It
has also been applied in autoimmune
diseases such as systemic lupus
erythematosus for similar purposes
(Chaussabel et al., 2008). In this report,
we compare the molecular features of
DM and psoriasis and apply molecular
profiling to aid in the diagnosis of an
ambiguous case of DM.
Our index case, a 32-year-old
woman, presented in June 2005 with the
3-month onset of well-demarcated viola-
ceous erythematous, scaling plaques on
her elbows, extensor forearms, dorsal
hands, lateral thighs, knees, and lower
legs, concerning for either psoriasis or
Gottron’s sign of DM (Figure 1a–c).
Diffuse erythema was also present on
her scalp and periungual areas, but she
did not display psoriatic nail changes,
geographic tongue, or heliotrope sign.
Antinuclear antibodies were positive
(titer 1:2,560) with a homogenous
pattern. Other antibodies including
anti-Jo1, SSA, SSB, anti-dsDNA, and
anti-centromere were negative. Given
her clinical ambiguity, a biopsy of one
of these psoriasis-like lesions on the knee
was performed. The biopsy demon-
strated regular epidermal acanthosis,
parakeratosis, mild, superficial peri-
vascular infiltrate, and dilated papillary
dermal vessels consistent with psoriasis
(Figure 1d). No interface dermatitis
was detected. However, a colloidal
iron stain revealed abundant mucin
throughout the dermis (Figure 1e),
which is unusual in psoriasis and
more consistent with DM. Given the
inconclusive results from traditional
histopathology, genome-wide expres-
sion analysis was applied to determineAccepted article preview online 3 June 2013; published online 27 June 2013
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whether an investigation into the mole-
cular nature of the lesion could aid in
clinical diagnosis. All patients signed
consent, and our study complied with
the Declaration of Helsinki principles
and was approved by the Stanford Insti-
tutional Review Board.
First, we compared the molecular
differences between psoriasis and DM.
Lesional skin biopsies were obtained
from 34 DM and 33 psoriasis patients
in an independent cohort (Yao et al.,
2008) and subjected to one-way
hierarchical clustering (based in
individual genes but not samples) to
identify the gene expression patterns
that differentiated these disease
processes (Supplementary Methods
online). Both psoriasis and DM reveal
strong activation of type I IFN and T-cell
signaling pathways (Figure 2a and c;
Caproni et al., 2004; Lew et al., 2004;
Greenberg et al., 2005; Wenzel et al.,
2006; Yao et al., 2008). In addition,
both diseases display a characteristic
downregulation of genes involved in
lipid metabolism (Gudjonsson et al.,
2009; Pietrzak et al., 2010). The
pathways that distinguished DM
from psoriasis included genes involved
in mucin and extracellular matrix
synthesis, complement components,
and angiogenesis, which were
upregulated specifically in DM (Scott
and Arroyave, 1987). Psoriasis, on the
other hand, revealed an upregulation of
genes involved in epidermal differentia-
tion, proliferation, and antimicrobial
response (Van de Kerkhof and Van Erp,
1996; de Jongh et al., 2005), which
agrees with the disease pathogenesis of
psoriasis at the molecular level and also
validates our approach.
Next, we compared the molecular
profile of the lesional skin of our patient
with independent skin biopsies from
confirmed DM and psoriasis patients.
Our patient’s lesion was obtained from a
portion of the original biopsy submitted
for histopathology taken from a psoria-
tic-appearing plaque on the knee.
Figure 1. Clinical and histological features of dermatomyositis and psoriasis in a 32-year-old woman. (a) Scaly violaceous plaques and papules over
metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints. Periungual telangiectasia. (b) Well-demarcated erythematous plaques with
micaceous scale on knees. (c) Scaly erythematous plaques on extensor aspects of forearm. (d) Skin biopsy of psoriatic plaque on knee reveals confluent
parakeratosis, loss of granular layer, epidermal acanthosis, and dilated papillary vessels. Bar¼ 100mM. Hematoxylin and eosin, X20, original magnification.
(e) Colloidal iron stain skin biopsy demonstrating abundant mucin (blue) in the dermis. Bar¼ 180mM.
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Two-way unsupervised hierarchical
clustering demonstrated that the patient
sample clustered within the DM
samples, suggesting that, despite the
equivocal histology, our patient’s sample
was molecularly more similar to DM
than psoriasis (Figure 2b and c). Principal
components analysis, adjusted for any
batch processing effects, also con-
firmed the molecular similarity of this
patient to the DM patient population
(Figure 2d).
To understand which gene signaling
pathways drove the clustering of our
patient’s biopsy with DM, we performed
one-way hierarchical clustering (based
on genes but not on samples), which
allowed placement of the patient’s
expression data in the center of the
dendrogram for easy comparison with
the psoriasis (left) and DM (right)
samples (Figure 2e). The Pearson’s cor-
relation coefficient was calculated
between our sample and the mean of
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Figure 2. Genome-wide analysis of lesional skin specimens of psoriasis and dermatomyositis (DM). (a) One-way unsupervised clustering of genes in lesional
skin specimens from 33 independent psoriatic patients and 34 DM patients. Venn diagram depicts functional pathways induced (red) and repressed (green) in DM
and psoriasis. (b, c) Unsupervised hierarchical clustering of 68 tissue biopsies including psoriasis, DM, and our patient’s biopsy (arrow). Array elements that varied at
least 1.5-fold from the median on at least six microarrays were included (3,048 genes). Dendrogram depicts our patient’s sample (red) clustering among the DM
samples. Data are displayed as a hierarchical cluster where rows represent genes and columns represent samples. Colored pixels capture the magnitude of the
differential expression for any gene. Shades of red and green represent induction and repression, respectively, relative to the median for each gene. Black pixels reflect
no change from the median. (d, left) Principal components analysis (PCA) plot unscaled using all probes for DM and psoriasis and our patient sample (red, right).
PCA plot with median scaling batch adjustment for the psoriasis and DM samples using significant probe sets with a t-test Po0.01 and |FC|41.5 between
psoriasis and DM. (e, above) One-way unsupervised clustering of genes with placement of lesional skin biopsy from our patient in the center of DM and psoriasis
samples. Eight clusters are identified, labeled 1–8, which correspond to different gene expression patterns between the psoriasis and DM samples. (Below) Graph of
Pearson correlation coefficient between our sample and the mean of the psoriasis (red) or DM (blue) gene expression values across 100 genes (moving window).
(f) List of significant genes and functional pathways found in each cluster. ECM, extracellular matrix; PSO, psoriasis; VEGF, vascular endothelial growth factor.
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both the psoriasis or DM gene expres-
sion values using a 100-gene moving
window (Figure 2e).
Interestingly, the gene expression
pattern was very similar among our
patient, DM, and psoriasis over clusters
3, 5, 7, which had enrichment of
genes involved in lipid metabolism,
type I IFN pathway activation, and
T-cell function (Figure 2f). However,
for clusters 1, 2, 4, and 6, our patient
displayed gene expression patterns
more consistent with DM than psor-
iasis. These clusters were enriched
with genes involved in lipid metabo-
lism, extracellular matrix synthesis,
mucin synthesis, complement cascade,
and angiogenesis. There was a cluster
of genes involved in proliferation and
cell cycle differentiation (cluster 8)
where our patient showed molecular
similarity to psoriasis. This observation
is consistent with the increased epi-
dermal thickness (and proliferation)
seen on histology.
Four years after presentation, our
patient developed proximal muscle
weakness and dysphagia with corre-
sponding elevation in creatine kinase
and aldolase. Her electromyography
showed evidence of chronic inflamma-
tory proximal myopathy with active
dennervation features. Her skin rash
remained similar to initial presentation.
Thus, she fulfilled four out of five
criteria of Bohan and Peter (1975)
(rash, elevated muscle enzymes,
proximal weakness, and abnormal
electromyography), confirming a diagnosis
of DM. This case demonstrates the
diverse ways in which DM can present,
compares the molecular profile between
psoriasis and DM, and highlights the
utility of molecular profiling to aid in
diagnosis where histopathologic criteria
may be inconclusive.
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TO THE EDITOR
Erythema exsudativum multiforme majus
(EEMM) is a rare condition affecting both
skin and mucous membranes. It is
assumed that humoral immune reponses
may contribute to the pathogenesis of the
disease, and the presence of autoantibo-
dies was described in 7 of 10 EEMM
patients (Foedinger et al., 1995, 1996).
These autoantibodies were associated
with desmosomal staining by direct
immunofluorescence microscopy of skin
and by indirect immunofluorescenceAccepted article preview online 6 June 2013; published online 11 July 2013
Abbreviation: EEMM, erythema exsudativum multiforme majus
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